On September 07, 2026, European stock markets experienced pressure due to rising oil prices and a significant drop in Novartis NVS shares following the failure of a heart medication in clinical trials. The Stoxx Europe 600 index closed nearly flat, while energy stocks led the way due to increased commodity prices after the U.S. and Iran engaged in mutual attacks on tankers. In contrast, the media and insurance sectors experienced notable declines.
Novartis offers a dividend yield of 2.96%, with a payout ratio that suggests sustainability, aligning with the GF Value™ verdict indicating the stock is modestly overvalued at 22.5% above its intrinsic value. GF Score™ of 82/100 reflects strong profitability and momentum, indicating solid overall performance. Guru 13F activity shows that 17 gurus hold NVS, with 6 adding to their positions, indicating confidence in the stock despite recent setbacks. What’s Behind the News?
The recent drop in Novartis shares is primarily attributed to the disappointing results from the late-stage clinical trial of its heart medication, pelacarsen. This failure not only marks a significant setback for the company but also raises concerns about its pipeline of innovative drugs, particularly in the cardiovascular space. The news has sent shockwaves through the healthcare sector, leading to a notable decline in Novartis’s stock price, which saw its largest drop since April.
Novartis AG is a leading player in the healthcare industry, with a market capitalization of approximately $304.97 billion. The company is engaged in the development and manufacturing of innovative drugs, focusing on areas such as oncology, immunology, neuroscience, and cardiovascular health. With a global presence, Novartis generates nearly one-third of its revenue from the United States, underscoring its importance in the pharmaceutical landscape.
Is NVS’s Dividend Safe and Attractive?
Novartis currently offers a dividend yield of 2.96%, which is considered attractive in the current market environment. The company’s payout ratio is sustainable, suggesting that it can maintain its dividend payments even amid recent challenges. Furthermore, Novartis has a history of dividend growth, which adds to its appeal as a dividend stock. The GF Value™ analysis indicates that the stock is currently trading at $159.99, which is 22.5% above its intrinsic value of $130.57. This modest overvaluation may temper expectations for immediate capital appreciation, but the dividend yield remains a compelling reason for income-focused investors. For more details, visit the GF Value™ page.
What Does NVS’s GF Score™ Tell Us?
The GF Score™ is a proprietary measure that evaluates a company’s financial strength, profitability, growth potential, valuation, and momentum. Novartis’s GF Score™ of 82/100 indicates a strong overall performance, particularly in profitability and momentum, with ranks of 8/10 and 9/10, respectively. However, its financial strength rank of 5/10 suggests that there may be some concerns regarding its balance sheet stability.
Metric Rating GF Score™ 82 Financial Strength 5/10 Profitability 8/10 Growth 6/10 Valuation 6/10 Momentum 9/10
Overall, Novartis demonstrates strengths in profitability and momentum, which are critical for long-term growth. However, the financial strength rank indicates that investors should keep an eye on the company’s balance sheet and liquidity as it navigates recent challenges. For further insights, visit the NVS stock page.
What Are Gurus and Insiders Doing with NVS?
Currently, 17 gurus hold positions in Novartis, with 6 adding to their stakes in recent quarters, while 10 have trimmed their holdings. This mixed activity suggests that while some investors remain confident in the company’s long-term prospects, others may be cautious following the recent clinical trial setback. Notably, there has been no insider buying or selling activity reported in the last three months, indicating a wait-and-see approach among insiders.

What This Means for Investors
In summary, while Novartis faces challenges following the clinical trial failure, its dividend yield and sustainability remain attractive for income-focused investors. The strong GF Score™ reflects solid profitability and momentum, but the modest overvaluation suggests caution. Investors should monitor the company’s financial health and market position as they consider their investment strategies. For more detailed analysis, check out the NVS stock page.
Frequently Asked Questions
What is NVS’s GF Score™?
NVS’s GF Score™ is 82/100, indicating strong performance in profitability and momentum, although financial strength is a concern.
Is NVS’s dividend safe?
Yes, NVS offers a dividend yield of 2.96% with a sustainable payout ratio, making its dividend attractive for investors.
What is NVS’s P/E ratio compared to historical?
NVS has a trailing P/E ratio of 24.59x, significantly higher than its 5-year median P/E of 16.98x, indicating it may be overvalued at present.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].